Rosen joined Lowey Dannenberg and Robbins Geller in examining The Ensign Group after June 2026 short-seller allegations tied to care-quality metrics, related-party billing, and possible Medicare and Medicaid fraud.
Multiple law firms have launched or expanded investor investigations into The Ensign Group, Inc. following June 2026 short-seller reports from Hunterbrook and Muddy Waters Research. Lowey Dannenberg said it is investigating potential violations of U.S. federal securities laws, while Rosen Law Firm said it is probing potential securities claims and preparing a class action; Robbins Geller had earlier announced a similar investigation. The scrutiny follows Hunterbrook's June 8, 2026 allegations of systemic quality-measure gaming, falsified care-quality data, inadequate patient care, understaffing, and improper related-party billing, as well as Muddy Waters' June 11, 2026 allegations of possible Medicare and Medicaid fraud involving rented administrator licenses. Rosen said Ensign shares fell 8.15% on June 8 after the Hunterbrook-related news, and the other releases said the stock fell further after the Muddy Waters report.